<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198091</url>
  </required_header>
  <id_info>
    <org_study_id>DY-SH-1601</org_study_id>
    <nct_id>NCT03198091</nct_id>
  </id_info>
  <brief_title>Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris</brief_title>
  <official_title>An Open Label, Single Arm, Multiple Center Study Observing the Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Coronary Artery Disease of Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Wanbang Pharmaceutical Marketing Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is designed to investigate factors affecting the efficacy of Dun Ye Guan Xin
      Ning tablet on patients with stable angina. The potential hypothesis is that Dun Ye Guan Xin
      Ning has a better effect on different subgroup patients with certain characteristics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 1000 eligible patients enrolled from 20 centers will take standard medications of
      care for stable angina plus Dun Ye Guan Xin Ning tablet for 6 months. Symptoms,
      questionnaires (SAQ, PSQI, and angina pectoris quantitative table of Chinese medicine
      symptoms scale), lipid, fasting glucose, homocysteine, EKG, blood pressure and other physical
      examination will be collected at baseline and follow-up. Among them, 200 patients will
      measure and inflammation biomarkers and endothelial function for further evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angina pectoris symptom</measure>
    <time_frame>6 month</time_frame>
    <description>Improvement od angina pectoris symptom</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Life quality</measure>
    <time_frame>6 month</time_frame>
    <description>using seattle Angina Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>6 month</time_frame>
    <description>using pittsburgh sleep quality index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest tightness</measure>
    <time_frame>0, 1 month, 3 month, 6 month</time_frame>
    <description>using angina pectoris quantitative table of Chinese medicine symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>6 month</time_frame>
    <description>levels of TG，TC, LDL, HDL, HCY, IL-6、TNF-α、and CRP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vascular endothelial function</measure>
    <time_frame>0, 1 month, 3 month, 6 month</time_frame>
    <description>using ZX7M-Endo-pat2000</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dun Ye Guan Xin Ning mono-therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dun Ye Guan Xin Ning</intervention_name>
    <description>Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.</description>
    <arm_group_label>Dun Ye Guan Xin Ning mono-therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18 and 75 years.

          2. Documented stable angina pectoris.

          3. During a period of time (more than 3 months), the duration, severity and the threshold
             of angina is relatively stable.

          4. Patients with at least one of the following events: ① patients who have done PCI or
             CABG for more than half a year; ② coronary CTA angiography or coronary angiography
             showed at least one major coronary artery stenosis ≥ 50%. Symptom occurs at least once
             per month.

          5. Medications remain stable within 1 month before the enrollment.

          6. Patients have the ability to understand the study, and can cooperate with researchers
             to carry out the test.

          7. Signed inform consent.

        Exclusion Criteria:

          1. Patents with coronary heart disease acute coronary syndrome during the last 6 months.

          2. Patients with aortic stenosis, hypertrophic cardiomyopathy and other diseases leading
             to angina.

          3. Patients have other heart disease, severe neurosis, menopausal syndrome,
             hyperthyroidism, cervical spondylosis, biliary heart disease, gastroesophageal reflux
             caused by chest pain.

          4. Patients combined with severe cardiopulmonary insufficiency (NYHA grade III ord IV),
             pulmonary insufficiency graded reference COPD clinical severity of lung function grade
             III (FEV1 / FVC &lt;70%, 30% 1 / FVC% of predicted value &lt;50%) and grade IV), severe
             arrhythmia (eg. III degree atrioventricular block)

          5. Patients combined with liver, kidney, hematopoietic system and other serious primary
             disease patients (TBil ≥ 1.5ULN, AST ≥ 2ULN, ALT ≥ 2ULN, serum creatinine ≥ 1.5ULN, Hb
             &lt;9mg/dL).

          6. Patients with cognitive, intellectual, or mental disorders.

          7. Those who can not take oral medication.

          8. Allergy to any component of this product.

          9. Patients received the trial medication within 28 days prior to the first treatment of
             this product.

         10. Lactating or pregnant women.

         11. Patients who are unwilling or unable to contraceptive in the reproductive period.

         12. Poor medication compliance.

         13. Other circumstances that the investigator considers unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Huo, MD</last_name>
    <phone>8610-83572283</phone>
    <email>huoyong@263.net.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Zhang, MD</last_name>
    <phone>8610-83575728</phone>
    <email>drzhy1108@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhang, MD</last_name>
      <phone>8610-83575728</phone>
      <email>drzhy1108@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Yong Huo</investigator_full_name>
    <investigator_title>Director of the Department of Cardiology and heart center of Peking University First Hospital</investigator_title>
  </responsible_party>
  <keyword>stable angina pectoris</keyword>
  <keyword>Dun Ye Guan Xin Ning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

